This is a preview of subscription content, log in via an institution to check access.
Notes
Costs were presented in 2018 US dollars and a 3% annual discount rate was applied to costs and QALYs.
Reference
Wayda B, et al. Cost-effectiveness and system-wide impact of using Hepatitis C-viremic donors for heart transplant. Journal of Heart and Lung Transplantation : 13 Sep 2021. Available from: URL: http://doi.org/10.1016/j.healun.2021.09.002
Rights and permissions
About this article
Cite this article
Transplanting HCV-positive hearts may be cost effective and improve waitlist times in the USA. PharmacoEcon Outcomes News 890, 29 (2021). https://doi.org/10.1007/s40274-021-08152-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08152-x